Mirum acquires Bluejay Therapeutics to expand rare liver disease pipeline [Yahoo! Finance]
Mirum Pharmaceuticals, Inc. - common stock (MIRM)
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Agreed in December 2025, the transaction is valued at up to $820m and brings the late-stage monoclonal antibody brelovitug, a candidate for chronic hepatitis delta virus (HDV), into Mirum's global portfolio. With this deal closure, Mirum secures worldwide rights to the fully human antibody, currently in trials for HDV, a condition lacking approved therapies in the US. Brelovitug has received breakthrough therapy designation from the US Food and Drug Administration (FDA) and prime designation from the European Medicines Agency. According to the agreement, Mirum acquired all outstanding shares of Bluejay Therapeutics through a combination of cash and Mirum common stock, along with possible tiered sales-based milestone payments. Simultaneously, Mirum completed private placement financings with commitments from existing and new healthcare investors, raising nearly $268.5m. These proceeds are allocated for commercialisation activities and clinical development of brelovitug in HD
Show less
Read more
Impact Snapshot
Event Time:
MIRM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MIRM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIRM alerts
High impacting Mirum Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
MIRM
News
- Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille SyndromeBusiness Wire
- Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)Business Wire
- Mirum doubles down on diversified rare disease strategy [Yahoo! Finance]Yahoo! Finance
- Is Mirum Pharmaceuticals on a Strong Path to Profitability? [Yahoo! Finance]Yahoo! Finance
- Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target raised by analysts at Morgan Stanley from $95.00 to $123.00. They now have an "overweight" rating on the stock.MarketBeat
MIRM
Earnings
- 11/4/25 - Beat
MIRM
Sec Filings
- 2/3/26 - Form 4
- 2/3/26 - Form 4
- 2/3/26 - Form 4
- MIRM's page on the SEC website